Literature DB >> 17476343

Immune surveillance of tumors.

Jeremy B Swann1, Mark J Smyth.   

Abstract

The ability of the immune system to identify and destroy nascent tumors, and to thereby function as a primary defense against cancer, has been debated for many decades. Recent findings by a number of investigators in both mouse models of cancer and humans with cancer now offer compelling evidence that particular immune cell types, effector molecules, and pathways can sometimes collectively function as extrinsic tumor suppressor mechanisms. This work provides the basis for further study of natural immunity to cancer and for rational use of this information in the design of immunotherapies in combination with other conventional cancer treatments.

Entities:  

Mesh:

Year:  2007        PMID: 17476343      PMCID: PMC1857231          DOI: 10.1172/JCI31405

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  122 in total

1.  Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism.

Authors:  Alessandra Mazzoni; Vincenzo Bronte; Alberto Visintin; Jessica H Spitzer; Elisa Apolloni; Paolo Serafini; Paola Zanovello; David M Segal
Journal:  J Immunol       Date:  2002-01-15       Impact factor: 5.422

2.  Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice.

Authors:  Erika Cretney; Kazuyoshi Takeda; Hideo Yagita; Moira Glaccum; Jacques J Peschon; Mark J Smyth
Journal:  J Immunol       Date:  2002-02-01       Impact factor: 5.422

3.  Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone.

Authors:  T A Davis; D G Maloney; D K Czerwinski; T M Liles; R Levy
Journal:  Blood       Date:  1998-08-15       Impact factor: 22.113

4.  Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer.

Authors:  I Saeterdal; J Bjørheim; K Lislerud; M K Gjertsen; I K Bukholm; O C Olsen; J M Nesland; J A Eriksen; M Møller; A Lindblom; G Gaudernack
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

5.  Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice.

Authors:  Takuma Hayashi; Denise L Faustman
Journal:  Cancer Res       Date:  2002-01-01       Impact factor: 12.701

6.  Partial regression in primary carcinoma of the lung: does it occur?

Authors:  K M Kerr; S K Johnson; G King; M M Kennedy; J Weir; R Jeffrey
Journal:  Histopathology       Date:  1998-07       Impact factor: 5.087

7.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.

Authors:  Y Naito; K Saito; K Shiiba; A Ohuchi; K Saigenji; H Nagura; H Ohtani
Journal:  Cancer Res       Date:  1998-08-15       Impact factor: 12.701

8.  FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation.

Authors:  T Kataoka; M Schröter; M Hahne; P Schneider; M Irmler; M Thome; C J Froelich; J Tschopp
Journal:  J Immunol       Date:  1998-10-15       Impact factor: 5.422

9.  Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.

Authors:  D H Kaplan; V Shankaran; A S Dighe; E Stockert; M Aguet; L J Old; R D Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

10.  Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development.

Authors:  Kazuyoshi Takeda; Mark J Smyth; Erika Cretney; Yoshihiro Hayakawa; Nobuhiko Kayagaki; Hideo Yagita; Ko Okumura
Journal:  J Exp Med       Date:  2002-01-21       Impact factor: 14.307

View more
  473 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function.

Authors:  Moshe Elkabets; Vera S G Ribeiro; Charles A Dinarello; Suzanne Ostrand-Rosenberg; James P Di Santo; Ron N Apte; Christian A J Vosshenrich
Journal:  Eur J Immunol       Date:  2010-12       Impact factor: 5.532

3.  Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47.

Authors:  Mark P Chao; Siddhartha Jaiswal; Rachel Weissman-Tsukamoto; Ash A Alizadeh; Andrew J Gentles; Jens Volkmer; Kipp Weiskopf; Stephen B Willingham; Tal Raveh; Christopher Y Park; Ravindra Majeti; Irving L Weissman
Journal:  Sci Transl Med       Date:  2010-12-22       Impact factor: 17.956

4.  Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrence.

Authors:  Shawn M Jensen; Christopher G Twitty; Levi D Maston; Paul A Antony; May Lim; Hong-Ming Hu; Ulf Petrausch; Nicholas P Restifo; Bernard A Fox
Journal:  J Immunol       Date:  2012-06-20       Impact factor: 5.422

5.  Identification of an Immunogenic Subset of Metastatic Uveal Melanoma.

Authors:  Luke D Rothermel; Arvind C Sabesan; Daniel J Stephens; Smita S Chandran; Biman C Paria; Abhishek K Srivastava; Robert Somerville; John R Wunderlich; Chyi-Chia R Lee; Liqiang Xi; Trinh H Pham; Mark Raffeld; Parthav Jailwala; Manjula Kasoji; Udai S Kammula
Journal:  Clin Cancer Res       Date:  2015-12-28       Impact factor: 12.531

6.  Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus.

Authors:  Kristian Taipale; Ilkka Liikanen; Juuso Juhila; Riku Turkki; Siri Tähtinen; Matti Kankainen; Lotta Vassilev; Ari Ristimäki; Anniina Koski; Anna Kanerva; Iulia Diaconu; Vincenzo Cerullo; Markus Vähä-Koskela; Minna Oksanen; Nina Linder; Timo Joensuu; Johan Lundin; Akseli Hemminki
Journal:  Mol Ther       Date:  2015-08-27       Impact factor: 11.454

7.  Nanotechnology for the Development of Nanovaccines in Cancer Immunotherapy.

Authors:  Maria Aurora Grimaudo
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  Mining the human autoantibody repertoire: isolation of potent IL17A-neutralizing monoclonal antibodies from a patient with thymoma.

Authors:  Roger R Beerli; Monika Bauer; Andrea Fritzer; Lindsey B Rosen; Regula B Buser; Markus Hanner; Melanie Maudrich; Mario Nebenfuehr; Jorge Alejandro Sepulveda Toepfer; Susanne Mangold; Anton Bauer; Steven M Holland; Sarah K Browne; Andreas Meinke
Journal:  MAbs       Date:  2014       Impact factor: 5.857

9.  Association between allergies and risk of pancreatic cancer.

Authors:  Michelle Cotterchio; Elizabeth Lowcock; Thomas J Hudson; Celia Greenwood; Steven Gallinger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-02-19       Impact factor: 4.254

Review 10.  Harnessing the immune system to treat cancer.

Authors:  Nina Bhardwaj
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.